Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) – preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial

Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) – preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial

Abstract Background Neuroprotection and promotion of remyelination represent important therapeutic gaps in multiple sclerosis (MS). Acute optic neuritis (ON) is a frequent MS manifestation. Based on the presence and properties of sphingosine-1-phosphate receptors (S1PR) on astrocytes and oligodendro...

Full description

Bibliographic Details
Main Authors: Christian Albert, Janine Mikolajczak, Anja Liekfeld, Sophie K. Piper, Michael Scheel, Hanna G. Zimmermann, Claus Nowak, Jan Dörr, Judith Bellmann-Strobl, Claudia Chien, Alexander U. Brandt, Friedemann Paul, Olaf Hoffmann
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Neurology
Subjects:
Optic neuritis
Fingolimod
Interferon Beta-1b
Remyelination
Multifocal VEP
Online Access:http://link.springer.com/article/10.1186/s12883-020-01645-z

Internet

http://link.springer.com/article/10.1186/s12883-020-01645-z

Similar Items